Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable…

Overview of attention for article published in Journal of Clinical Oncology, October 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news: 7 news outlets
blogs: 1 blog
twitter: 29 X users

patent: 3 patents
facebook: 1 Facebook page
guideline: 2 clinical guideline sources

Readers on

mendeley: 419 Mendeley

So far, Altmetric has seen 33 X posts from 29 X users, with an upper bound of 209,286 followers.

This cost effectiveness analysis was based on a 2018 Phase II study of stage III/IV unresectable melanoma patients randomized to ipi alone or ipi + Tvec here: https://t.co/jhFqZhACZq

New2Trip: Randomized, Open-Label Phase II Study Evaluating Efficacy & Safety of Talimogene Laherparepvec in Co… https://t.co/UKFIGYOr9C

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 29 additional X posts.